LFS, described in 1969 [29] and ultimately linked to germline mutations in Tp53 [30], stands as a prototypic cancer predisposition syndrome in the evolution from discovery to effective intervention in a broad array of cancer types like those observed in DBA. The gene discussed is TP53; the disease is cancer.